Beyond Ultrasound Diagnostics to Therapy... Samsung Medison Partners with U.S. HistoSonics

Integration of Premium Ultrasound R20 and Cancer Treatment System

"Securing Future Growth Engines Through Strategic Partnership"

Samsung Medison is securing future growth engines by leveraging the scalability of its ultrasound technology.

On March 9, Samsung Medison announced that it will significantly expand its portfolio from diagnostics to therapy through a strategic partnership with HistoSonics, a global leader in noninvasive ultrasound-based cancer treatment.

HistoSonics has commercialized the 'histotripsy' technology, which mechanically destroys tumor tissue using ultrasound without surgical incisions. The 'Edison' system, which incorporates this technology, received De Novo approval from the U.S. Food and Drug Administration (FDA) in 2023, earning recognition as an innovative medical device. The company recently raised an investment of approximately $2.25 billion (about 3 trillion won), demonstrating its growth potential.

This partnership will enable real-time integration between Samsung Medison's premium ultrasound diagnostic device, R20, and the Edison system. High-resolution, real-time ultrasound images acquired by R20 can now be reliably transmitted to the Edison system. In particular, the image signal processing architecture and system interface have been completely redesigned to precisely reflect the intense acoustic environment generated during histotripsy procedures.

The integrated Edison system utilizes histotripsy technology to precisely focus ultrasound on the tumor site, generating and collapsing microbubbles to selectively destroy tumor tissue. As this is a noninvasive procedure that does not require incisions, it reduces the recovery burden on patients. Furthermore, the addition of high-quality real-time imaging technology enhances targeting accuracy and further improves the overall precision and safety of the procedure.

The two companies plan to pioneer new markets and lead innovation in future medical solutions by combining Samsung Medison's advanced diagnostic imaging technology with HistoSonics' therapeutic expertise.

Mike Blue, CEO of HistoSonics, stated, "By integrating the R20 and Edison systems, we will enable clinicians to perform procedures with even greater accuracy in an optimized, high-resolution imaging environment, resulting in improved patient care."

Yoo Kyutae, CEO of Samsung Medison, said, "This collaboration represents a pivotal turning point in connecting diagnostics and therapy based on the scalability of ultrasound technology. We will further diversify our business portfolio and secure future growth engines by expanding strategic partnerships with promising global companies."

This content was produced with the assistance of AI translation services.